New CFO Receives Billion-Dollar Bonus: Changes in Edwards Lifesciences Executive Shares

Edwards Lifesciences Corp (NYSE: EW) has entered into an employment and bonus agreement with incoming Chief Financial Officer Theodora Mistras, following an offer accepted on May 2, 2026. Under the agreement, Mistras will receive an annual base salary of $925,000, a target performance bonus equal to 100% of her base salary, and a cash sign-on bonus of $2.013 million. She will also be granted $8 million in new restricted stock units (RSUs), $4.5 million in annual equity awards for 2026, cash severance and accelerated RSU vesting upon termination or a change in control, and relocation assistance from New York to Orange County, California, among other comprehensive terms.

On May 11–12, performance-based RSUs held by CEO Bernard Zobigian vested, converting into common shares valued between $3.7 million and $3.8 million. After satisfying tax withholding obligations, transferring some shares into a trust, and selling approximately $2.9 million worth of shares under a 10b5-1 plan, he still retains several million dollars’ worth of Edwards stock.

On May 15, Senior Vice President of Strategy and Corporate Development Donald Bobo Jr. sold about $1.46 million worth of shares in the open market; however, he continues to hold an economic interest of tens of millions of dollars across direct holdings, trusts and his 401(k) plan.

In its first-quarter 2026 results announced April 23, the company reported double-digit sales growth driven by strong demand for its structural heart disease treatment products and reaffirmed its outlook that full-year operating margin will reach the top end of its 28 – 29% guidance range. Recently, Edwards has participated in major healthcare conferences hosted by Bank of America and Citi and launched its “Stay in the Race” campaign to encourage early intervention in valvular heart disease, further boosting product awareness and market access.

Headquartered in Irvine, California, Edwards Lifesciences is a global leader in structural heart disease therapies—such as transcatheter aortic valve replacement (TAVR)—and hemodynamic monitoring. With an aging population, a rising incidence of cardiovascular disease and expanding TAVR indications, demand for structural heart solutions is growing, drawing attention to the long-term growth prospects of the medical device industry.